Q3 2020 Sales Performance

Gepotidacin: a first in class novel oral antibiotic Potential to transform treatment landscape for patients with limited therapeutic options UUTIS: common health problem with need for new options for resistant infections Over 50% of all women develop at least one UTI in their lifetime and >24% experience recurrent UTIs¹ 10.5m office visits for UTI symptoms and ~11m prescriptions annually in the US2,3 Current treatment options are established generic antibiotics but increasing antimicrobial resistance (AMR) drives need for alternatives to current antibiotics Gepotidacin: Novel mechanism of action; Active against most antibiotic resistant bacteria Twice daily, oral dosing, short course (5 days uUTI, 1 day GC) 650 subjects have received gepotidacin to date Majority AEs mild-to-moderate & do not lead to discontinuations Phase 3 studies initiated for uUTIs and urogenital gonorrhea; results expected 1H 2022 (for uUTI, interim analysis) UUTIS - uncomplicated Urinary Tract Infections GC urogenitial gonorrhea 1. Foxman,B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. The American Journal of Medicine. 2002; 113(1):5-13 2. Flores-Mireles AL, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-284 3. Foxman, B, et.al.. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000; 10: 509-515 gsk Market research shows ~40% of uUTI patients have infections with antibiotic resistance4 8% 11% I - 38% 62% 19% 4. GSK US physician market research, 2019 No known resistance Resistant to 1 antibiotic Resistant to 2 antibiotics Resistant to 3+ antibiotics 62 2

View entire presentation